Description: The true cost of a drug and its therapeutic outcome is impacted by a myriad of factors. This session will utilize case studies in high-cost, chronic diseases to illustrate to participants what factors can be critical to evaluating the true cost of a pharmaceutical intervention. Differing from session one, session two will focus on site of care, buy-and-bill aspects, and the differences between a medical and pharmacy benefit and how these factors ultimately impact the total cost of patient care.

Description: When actuaries and consultants evaluate various pharmaceuticals for inclusion in an employer’s benefits offering, it can be commonplace to look at the advertised list price, or WAC (wholesale acquisition cost), between products and use that as a primary driver in the evaluation process.

Description: Our panel of experts will explore 'Blue Zone' communities, the common denominators slowing the aging process and the potential impacts these initiatives could have on disability and long-term care insurance.

Description: Get up to date on the current and potential use of artificial intelligence (AI) in the health care space. In this interactive session, you will learn how AI is being used today and discover its potential to reshape and revolutionize health care. Take advantage of the opportunity to find out how AI can influence patient experience in every phase of health care delivery, and join the conversation about the challenges and limitations that arise with the use of this technology.

Description: Discuss changes in group life waiver of premium claim recovery and mortality experience since the 2005 table was released, the development of the 2023 table, and the new statutory valuation standard approved by the National Association of Insurance Commissioners (NAIC).

Description: In this session, participate in a mock negotiation of a typical value based contract taking on the role of either provider or payer and solving for the various negotiation challenges, objections, risk mitigations, data requirements, etc. from either party. Attendees will learn best practices and ideal tools and workflows to engage in when supporting VBC negotiations and gain insights into the typical challenges to equitable and agreeable terms.

Description: In this session, we will address the current landscape of the standalone Medicare Part D market and the challenges to its sustainability. Specifically, we will discuss some headwinds for plan sponsors due to the Inflation Reduction Act and future considerations for prescription drug plan (PDP) benefit design and pricing.

Description: Session 4B: Impact of GLP-1 Drugs on Health Care Cost Trend and Clinical Outcomes

Description: Virtual - Session 8A: Diagnostics in Focus - Innovations, Challenges and Actuarial Perspectives

Description: Virtual - Session 4A: Data Science-Driven MA Product Design Strategies